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Abstract To get insight into the insertion mechanism of small
newly synthesized single-spanning membrane proteins, Pf3 coat
protein mutants were constructed with potential glycosylation
sites in the N-terminus. Some of these proteins, when synthesized
in vitro in the presence of microsomes, became efficiently
glycosylated, proving that they insert into the membrane and
translocate their N-terminus to the lumenal side. Such Pf3
constructs also insert efficiently into Escherichia coli vesicles and
even in pure lipid vesicles, suggesting a common mechanism,
which might be spontaneous. Glycosylation was sensitive to
changes in the amino acid sequence of the N-terminus,
suggesting that it depends on the structure of the protein and/or
its positioning with respect to the lipid^water interface. ß 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The Pf3 major coat protein is the major constituent of the
protective coat of the ¢lamentous bacteriophage Pf3, which
infects Pseudomonas aeruginosa. It is a small protein of only
44 amino acids, which is stored in the inner membrane of the
bacterium during the infection cycle. In contrast to coat pro-
teins of closely related phages such as M13, fd or Pf1 (for a
review about ¢lamentous phages, see [1]), it is synthesized
without a leader sequence [2]. Its membrane insertion is in-
dependent of Sec proteins [3], but depends on the proton
motive force, which translocates the negatively charged
N-terminus across the membrane [4].
Due to its small size and simple topology, Pf3 coat protein
has been extensively used as a model system for the investi-
gation of membrane protein insertion in Escherichia coli, ei-
ther fused to other proteins [3,5,6], or by itself [4,7]. Since
certain Pf3 mutants are also able to insert into pure lipid
vesicles with many di¡erent lipid compositions, di¡erent as-
pects of the lipid speci¢city of membrane protein insertion
could be investigated [8,9]. In all these studies, protease acces-
sibility experiments were used to deduce the extent of inser-
tion and the topology of the protein.
An alternative tool to study membrane protein insertion
and topology is the glycosylation mapping technique. This
approach makes use of the fact that the active site of the
enzyme oligosaccharyl transferase (OST) is located in the lu-
men of the endoplasmic reticulum (ER) and lies at a ¢xed
distance above the membrane [10]. Potential glycosylation
sites are engineered into a protein, which is then synthesized
in vitro in the presence of microsomes. By determining which
sites can become glycosylated, information about the topology
of a protein is obtained (e.g. [11^14]). This technique has been
used to determine the e¡ects of di¡erent amino acid substitu-
tions on the positioning of transmembrane helices in a model
membrane protein [15,16].
The glycosylation mapping technique could be a valuable
additional tool to study the topology and positioning of Pf3
coat proteins in membranes. Vice versa, since much informa-
tion is available on its structural properties from studies on
model membrane systems [17,18], Pf3 could be a suitable
model protein to gain insight into the process of glycosylation.
In this study we have synthesized Pf3 mutants with potential
glycosylation sites in vitro in the presence of microsomes and
subsequently we have analyzed whether and to what extent
these mutants became glycosylated.
2. Materials and methods
2.1. Construction of mutants
A plasmid with the gene encoding the 3L-4N mutant ([7] ; see Fig.
1) was used as a template for QuikChange site-directed mutagenesis
(Stratagene). The AAA mutant, which has a less hydrophobic N-ter-
minal tail, was created by using two partially overlapping primers in a
single reaction, the 5P primer containing the V8A and L12A mutations
and the 3P primer containing the V15A mutation. This is a modi¢ca-
tion of the protocol of Kirsch and Joly where two non-overlapping
primers were used [19]. Subsequently, glycosylation sites were engi-
neered in these two proteins, resulting in the 3L-4N(glyc18) and
AAA(glyc18) mutants. These were constructed on the 3L-4N and
AAA templates in a QuikChange reaction by replacing the second
and third codons by base pairs encoding the glycosylation acceptor
site N-S-T. All mutations were con¢rmed by DNA sequencing.
2.2. Translocation of mutants into microsomes
Translocations were performed essentially as described [8]. After
transcription, the proteins were translated using an E. coli S-135 ly-
sate, which was prepared as described [20]. Translation/translocation
reactions included 5 WCi [35S]methionine to produce radiolabeled pro-
teins. Canine pancreatic microsomal membranes (Promega) were
present during the translation, 3.0 or 3.6 Wl per reaction and 7.0 or
6.4 Wl IMV bu¡er (50 mM triethanolamine acetate, pH 7.5, 250 mM
sucrose, 1 mM dithiothreitol) was added to adjust the total volume of
the translocation mixture to 50 Wl. After the translation/translocation
reaction an aliquot of 5 or 10 Wl was withdrawn to serve as a standard
and the rest was centrifuged in a TLA100 rotor at 60 000 rpm for 30
min at 4‡C in order to pellet the microsomes. After centrifugation, the
supernatant was removed and the pellet was resuspended into 40 Wl
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IMV bu¡er. The samples were subsequently trichloroacetic acid
(TCA)-precipitated.
2.3. Endo H treatment
For endoglycosidase H (Endo H) treatment, the microsomal pellet
was resuspended into 50 Wl of reaction bu¡er (100 mM sodium acetate
pH 5.5, containing 1 mM phenylmethylsulfonyl £uoride, 1 mM
EDTA, 2% (v/v) Triton X-100 and 10 Wg/ml each of the protease
inhibitors chymostatin, leupeptin, antipain and pepstatin). To be
able to analyze the proteins in the microsomal pellet, 5 Wl of this
mixture was directly precipitated to serve as a standard. The rest of
the mixture was divided into two portions, to which either 1 Wl of
H2O or 1 Wl of Endo H (Boehringer) was added. Subsequently these
mixtures were incubated at 37‡C for 1 h and then TCA-precipitated.
Proteins were visualized using Tricine^SDS^PAGE according to
[21] followed by autoradiography and quantitation on a PhosphoIm-
ager (Molecular Dynamics).
3. Results and discussion
We ¢rst investigated whether Pf3 mutants are able to insert
into ER membranes and subsequently can become glycosylat-
ed. The 3L-4N mutant already contains a potential glycosyl-
ation site in the N-terminal tail, namely N-V-T (see Fig. 1).
However, the asparagine of this site is located only 12 residues
before the start of the hydrophobic segment of the protein.
This might be too close to the membrane, since it was pre-
viously found for leader peptidase that the acceptor site has to
be 14^15 residues away from the N-terminal end of the trans-
membrane segment in order to be glycosylated [10]. Therefore
we constructed the 3L-4N(glyc18) mutant, in which an extra
glycosylation site is engineered at 18 residues from the hydro-
phobic segment, which should be su⁄ciently distant from the
membrane.
The 3L-4N(glyc18) mutant was produced in an in vitro
transcription/translation reaction, making use of an E. coli
lysate. Canine pancreatic microsomes were present during
the translation, to allow the protein that is produced to insert
into these membranes and to become glycosylated. As can be
seen in Fig. 2, this translation reaction produced two labeled
protein bands (lane 1). The lower one, which runs at the same
position on the gel as other Pf3 mutants in previous studies,
represents the 3L-4N(glyc18) protein [8,9]. The upper band
could represent the glycosylated form of the protein. When
the microsomes were pelleted by centrifugation, some of the
3L-4N(glyc18) protein was found in the supernatant (lane 2),
but most of it (50^60%) was associated with the microsomes
(lane 3). The higher molecular weight form of the protein was
found to be exclusively associated with the microsomes, where
it constitutes 35% of the total protein (for the quanti¢ed gly-
cosylation e⁄ciencies see Fig. 4). To determine whether this is
indeed glycosylated protein, the pellet was divided into two,
one half of which was treated with Endo H, an enzyme which
deglycosylates proteins. The other half of the pellet was mock-
treated. After treatment with Endo H for 1 h at 37‡C, the
upper band has disappeared and the lower band has increased
in intensity (compare lanes 4 and 5), while in the mock-treated
sample, the upper band is still present. The total amount of
labeled protein remains the same with or without Endo H
treatment (82 or 85% of originally pelleted protein respec-
tively). From this experiment, we conclude that the upper
band is the glycosylated form of the protein. Since the active
site of OST resides in the lumen of the ER, this demonstrates
that a substantial proportion of the proteins has inserted into
the microsomal membrane with their N-terminus translocated
into the lumen. This demonstrates that the N-terminus indeed
reaches the trans-side of the membrane in the in vitro system.
This observation supports the interpretation of previous in
vitro experiments, where protease protection assays were
used to get insight into the translocation of the N-terminus
into E. coli or lipid vesicles [4,7^9].
The ¢nding that the 3L-4N(glyc18) mutant inserts e⁄ciently
into microsomal membranes and E. coli inner membrane
vesicles (data not shown) suggests a common insertion path-
way. The observation that such a protein also inserts e⁄-
ciently into synthetic large unilamellar vesicles [8,9] proves
that membrane proteins are not required for insertion. This
leads to the suggestion that the insertion in microsomal mem-
branes is spontaneous, although it cannot be excluded that
membrane proteins are involved. The ¢nding that the protein
becomes glycosylated suggests, but does not prove, that gly-
cosylation can take place outside the context of the translo-
cation pathway.
The 3L-4N(glyc18) mutant is only glycosylated once, most
likely at the newly introduced glycosylation site 18 residues
away from the transmembrane segment, and not at the intrin-
sic glycosylation site at 12 residues. Indeed, when a similar
translocation experiment was performed with the 3L-4N mu-
tant (Fig. 3A), the glycosylation e⁄ciency was only 5% or less
(Fig. 4), although in principle N-V-T and N-S-T sites can
both be glycosylated e⁄ciently [22]. This suggests that a 12-
residue distance between the acceptor site and the transmem-
brane segment is too small for e⁄cient glycosylation.
The major coat proteins of ¢lamentous bacteriophages like
Pf3, M13, fd and Pf1 all have an N-terminus with an amphi-
pathic nature [18,23^25]. Thus the N-termini of the Pf3 mu-
tants probably possess speci¢c structural properties and a high
a⁄nity for the interface, which may in£uence the glycosyla-
tion process. To investigate this possibility, we constructed the
AAA mutant (Fig. 1) in which three hydrophobic residues
(two valines and a leucine) were changed to alanine residues.
When this AAA mutant is translated in the presence of micro-
somes, about 20% of the protein becomes glycosylated (Figs.
3B and 4). This demonstrates that, in contrast to the 3L-4N
mutant, in the AAA mutant the glycosylation site at 12 resi-
Fig. 1. Amino acid sequences of the Pf3 mutants used in this study. The glycosylation acceptor sites are underlined. The putative hydrophobic
transmembrane segment is shown in italics. Amino acid substitutions are shown in bold. The numbers above the sequence indicate the distance
from the asparagine in the glycosylation site to the ¢rst amino acid of the hydrophobic segment.
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dues from the hydrophobic segment can be reached by OST.
When the extra glycosylation site is introduced, resulting in
the AAA(glyc18) mutant (Fig. 1), some of the protein (around
5%) even becomes doubly glycosylated (Fig. 3B). The fact that
most of the protein is not doubly glycosylated is perhaps due
to steric hindrance.
The results clearly show that the 3L-4N mutant is glycosy-
lated signi¢cantly less e⁄ciently than the other mutants used
in this study (Fig. 4), which either have a glycosylation site
further from the transmembrane segment or a less hydropho-
bic N-terminus. Therefore glycosylation is indeed quite sensi-
tive to changes in the N-terminus of Pf3. Since OST glycosy-
lates N-A-T sites with similar e⁄ciency as N-V-T sites [22],
the di¡erences in glycosylation behavior between the 3L-4N
and the AAA mutants suggest that the position of the glyco-
sylation site at the N-terminus changes with respect to the
lipid^water interface as a result of the amino acid substitu-
tions.
There are several possible explanations for this di¡erence in
glycosylation behavior. First, substitution of two valines and
one leucine for alanines could make the conformation of the
N-terminus more extended, and thus a¡ect the positioning of
the glycosylation site with respect to the lipid^water interface.
However, this possibility is unlikely since the K-helical pro-
pensities of these amino acids di¡er only slightly from each
other, both in aqueous bu¡er and in non-polar solvents [26].
Second, since the N-terminus is less hydrophobic in the AAA
mutant than in the 3L-4N mutant, its interfacial a⁄nity is
reduced, which could cause the glycosylation sites to be lo-
cated further away from the surface of the membrane. Third,
the transmembrane segments of these mutants are bordered
by both hydrophobic and polar amino acids, but not by
charged residues. Therefore, there may be some £exibility in
the exact positioning of this segment. It is possible that the
di¡erence in hydrophobicity between the N-terminus of the
3L-4N and the AAA mutant a¡ects the precise positioning
of their transmembrane segments, thereby causing a di¡erent
positioning of the glycosylation sites with respect to the mem-
brane.
In the case of the AAA mutant, glycosylation could take
place while the Asn of the acceptor site was located 12 resi-
dues away from the start of the hydrophobic transmembrane
segment. Previous studies using leader peptidase as a model
protein indicated a sharp threshold for glycosylation of N-ter-
minal sites at a distance of 14^15 residues from the following
transmembrane segment [10]. An important di¡erence be-
tween the two proteins is that the transmembrane segment
of leader peptidase in these experiments was bordered on
the N-terminal side by a negatively charged Glu and therefore
has a much more clearly de¢ned boundary than the Pf3 mu-
tants [10]. The positioning of the transmembrane segment
could therefore be much more £exible in the Pf3 mutants,
allowing sites closer to the membrane to become glycosylated.
Another di¡erence is that glycosylation of leader peptidase
was independent of the sequence context, whereas glycosyla-
tion of Pf3 was very sensitive to the amino acid sequence of
Fig. 2. Translocation of the 3L-4N(glyc18) mutant in microsomes.
The protein was translated in the presence of microsomes and a
10% standard fraction (st.) was removed. The rest was centrifuged
and divided into supernatant (sup.) and pellet fractions. Of the pel-
let, 10% was directly precipitated and the rest was incubated at
37‡C for 1 h without (3EH) or with (+EH) Endo H. The arrow-
head indicates the position of the glycosylated protein.
Fig. 3. Translocation of (A) the 3L-4N and 3L-4N(glyc18) mutants
and (B) the AAA and AAA(glyc18) mutants into microsomes.
Translation was performed in the presence of microsomes and a
third of this reaction was put on gel as a standard (st.). The micro-
somes were pelleted by centrifugation and both supernatant (sup.)
and pellet fractions are shown. The arrowheads indicate the posi-
tions of singly and doubly glycosylated forms of the protein.
Fig. 4. Glycosylation e⁄ciencies of the di¡erent mutants. Transloca-
tions into microsomes were performed and the glycosylation e⁄cien-
cies in the total reaction mixture and microsomal pellets were deter-
mined. The average values and, where appropriate, standard
deviations are shown (3L-4N: n = 1, 3L-4N(glyc18): n = 8, AAA:
n = 2, AAA(glyc18): n = 4). For the AAA(glyc18) mutant, singly and
doubly glycosylated forms were combined.
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the N-terminus, most likely because the polypeptide chain of
leader peptidase is in a £exible extended conformation [10].
Finally, the di¡erent results obtained with the Pf3 mutants
on the one hand and leader peptidase on the other hand could
also be caused by di¡erent translocation mechanisms, since
the large protein leader peptidase inserts co-translationally
into the ER membrane in a SRP- and Sec-dependent manner
[10,27,28]. In contrast, as argued above, glycosylation of Pf3
might take place outside the context of the translocation path-
way. In addition, the Pf3 proteins are very small and most
likely insert post-translationally, since about 30^40 amino
acids will be covered by the ribosome [29^31] and thus the
transmembrane segment will not emerge before translation is
terminated. Therefore, it is very likely that translocation of
the Pf3 mutants takes place independently of the ribosome.
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